Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Many patients with Crohn’s disease (CD) undergo intestinal resection during the disease course. Despite surgery, postoperative recurrence (POR) commonly occurs. Although postoperative use of tumor necrosis factor α (TNF-α) inhibitors is known to be effective in preventing POR, few studies have evaluated the effectiveness of continuing the same TNF-α inhibitors postoperatively in patients who received TNF-ɑ inhibitors before surgery. Methods: This retrospective observational study was performed in a single tertiary medical center. We retrospectively reviewed patients who had undergone the first intestinal resection due to CD and divided them into two groups: TNF-α inhibitor users in both the preoperative and postoperative periods, and TNF-α inhibitor users in only the preoperative period. We compared the clinical outcomes between these two groups. Results: In total, 45 patients who used TNF-α inhibitors preoperatively were recruited. Among them, TNF-α inhibitors were used postoperatively in 20 patients (44.4%). The baseline characteristics except age at diagnosis were similar in both groups. The rates of surgical and endoscopic recurrence were not different between the two groups, but the cumulative clinical recurrence rate was significantly lower in the postoperative TNF-α inhibitors group (log-rank p=0.003). In multivariate Cox regression analysis, postoperative TNF-α inhibitors use was significantly associated with a decreased risk of clinical recurrence (adjusted hazard ratio, 0.204; 95% confidence interval, 0.060 to 0.691; p=0.011). Conclusions: Continuing TNF-α inhibitors postoperatively in patients who were receiving TNF-α inhibitors before surgery significantly reduced the rate of clinical recurrence. For patients with CD who received TNF-α inhibitors preoperatively, continuing their use after surgery could be recommended.
Abstract
Background/Aims: Many patients with Crohn’s disease (CD) undergo intestinal resection during the disease course. Despite surgery, postoperative recurrence (POR) commonly occurs. Although postoperative use of tumor necrosis factor α (TNF-α) inhibitors is known to be effective in preventing POR, few studies have evaluated the effectiveness of continuing the same TNF-α inhibitors postoperatively in patients who received TNF-ɑ inhibitors before surgery. Methods: This retrospective observational study was performed in a single tertiary medical center. We retrospectively reviewed patients who had undergone the first intestinal resection due to CD and divided them into two groups: TNF-α inhibitor users in both the preoperative and postoperative periods, and TNF-α inhibitor users in only the preoperative period. We compared the clinical outcomes between these two groups. Results: In total, 45 patients who used TNF-α inhibitors preoperatively were recruited. Among them, TNF-α inhibitors were used postoperatively in 20 patients (44.4%). The baseline characteristics except age at diagnosis were similar in both groups. The rates of surgical and endoscopic recurrence were not different between the two groups, but the cumulative clinical recurrence rate was significantly lower in the postoperative TNF-α inhibitors group (log-rank p=0.003). In multivariate Cox regression analysis, postoperative TNF-α inhibitors use was significantly associated with a decreased risk of clinical recurrence (adjusted hazard ratio, 0.204; 95% confidence interval, 0.060 to 0.691; p=0.011). Conclusions: Continuing TNF-α inhibitors postoperatively in patients who were receiving TNF-α inhibitors before surgery significantly reduced the rate of clinical recurrence. For patients with CD who received TNF-α inhibitors preoperatively, continuing their use after surgery could be recommended.
참고문헌 (41)
- Sang Hyoung Park, "Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases", Intestinal research, 18(1), pp.34~44 (2020), 대한장연구학회
- Baumgart DC, "Crohn’s disease", Lancet, 380, pp.1590~1605 (2012)
- Barrett JC, "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease", Nat Genet, 40, pp.955~962 (2008)
- Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease : the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
- Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease : a 30year review", Gut, 50, pp.485~489 (2002)
- Emiko Mizoguchi, "Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models", Intestinal research, 18(2), pp.151~167 (2020), 대한장연구학회[DOI]
- De Cruz P, "Postoperative recurrent luminal Crohn’s disease : a systematic review", Inflamm Bowel Dis, 18, pp.758~777 (2012)
- Nos P, "Postoperative Crohn’s disease recurrence : a practical approach", World J Gastroenterol, 14, pp.5540~5548 (2008)
- Sung Bae Kim, "Risk Factors for Postoperative Recurrence in Korean Patients with Crohn’s Disease", Gut and Liver, 14(3), pp.331~337 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- Michetti P, "Postsurgical prophylaxis in Crohn’s disease:which patients, which agents?", Dig Dis, 33(Suppl 1), pp.78~81 (2015)
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- D’Haens GR, "Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease : a controlled randomized trial", Gastroenterology, 135, pp.1123~1129 (2008)
- Peyrin-Biroulet L, "Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease : a meta-analysis", Am J Gastroenterol, 104, pp.2089~2096 (2009)
- Domènech E, "Impact of azathioprine on the prevention of postoperative Crohn’s disease recurrence : results of a prospective, observational, long-term follow-up study", Inflamm Bowel Dis, 14, pp.508~513 (2008)
- Savarino E, "Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease : a randomized controlled trial", Am J Gastroenterol, 108, pp.1731~1742 (2013)
- Armuzzi A, "Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease : an open-label pilot study", J Crohns Colitis, 7, pp.e623~e629 (2013)
- Regueiro M, "Infliximab prevents Crohn’s disease recurrence after ileal resection", Gastroenterology, 136, pp.441~450 (2009)
- Cañete F, "Adalimumab or infliximab for the prevention of early postoperative recurrence of Crohn disease : results from the ENEIDA Registry", Inflamm Bowel Dis, 25, pp.1862~1870 (2019)
- Narula N, "Meta-analysis : perioperative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease", Aliment Pharmacol Ther, 37, pp.1057~1064 (2013)
- El-Hussuna A, "Increased risk of postoperative complications in patients with Crohn’s disease treated with anti-tumour necrosis factor α agents : a systematic review", Dan Med J, 61, pp.A4975~ (2014)
- Hansen TM, "Management of biological therapy before elective inflammatory bowel disease surgeries", Inflamm Bowel Dis, 25, pp.1613~1620 (2019)
- Kulaylat AN, "The impact of preoperative anti-TNFα therapy on postoperative outcomes following ileocolectomy in Crohn’s disease", J Gastrointest Surg, 25, pp.467~474 (2021)
- Billioud V, "Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases : a meta-analysis", J Crohns Colitis, 7, pp.853~867 (2013)
- Best WR, "Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study", Gastroenterology, 70, pp.439~444 (1976)
- Buisson A, "Review article : the natural history of postoperative Crohn’s disease recurrence", Aliment Pharmacol Ther, 35, pp.625~633 (2012)
- Regueiro M, "Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection", Inflamm Bowel Dis, 17, pp.118~126 (2011)
- Henriksen M, "C-reactive protein : a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective populationbased study", Gut, 57, pp.1518~1523 (2008)
- De Cruz P, "Crohn’s disease management after intestinal resection : a randomised trial", Lancet, 385, pp.1406~1417 (2015)
- 유준환, "Fibrostenotic strictures in Crohn’s disease", Intestinal research, 18(4), pp.379~401 (2020), 대한장연구학회[DOI]
- Kenji Watanabe, "Clinical management for small bowel of Crohn’s disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion", Intestinal research, 18(4), pp.347~354 (2020), 대한장연구학회[DOI]
- De Cruz P, "Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients : a POCER study analysis", Aliment Pharmacol Ther, 42, pp.867~879 (2015)
- Sorrentino D, "Low dose infliximab for prevention of postoperative recurrence of Crohn’s disease : long term follow-up and impact of infliximab trough levels and antibodies to infliximab", PLoS One, 10, pp.e0144900~ (2015)
- Kotze PG, "Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn’s disease : results from the MULTIPER database", J Crohns Colitis, 9, pp.541~547 (2015)
- Kopylov U, "Anti-tumor necrosis factor and postoperative complications in Crohn’s disease : systematic review and meta-analysis", Inflamm Bowel Dis, 18, pp.2404~2413 (2012)
- Jones GR, "Systematic review : the use of thiopurines or anti-TNF in post-operative Crohn’s disease maintenance. Progress and prospects", Aliment Pharmacol Ther, 39, pp.1253~1265 (2014)
- Doherty GA, "Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn’s disease", Inflamm Bowel Dis, 18, pp.1608~1616 (2012)
- Guo Z, "Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn’s disease", Colorectal Dis, 20, pp.O267~O276 (2018)
- Ferrante M, "Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn’s disease recurrence", J Crohns Colitis, 9, pp.617~624 (2015)
- López-Sanromán A, "Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence : a GETECCU randomised trial", J Crohns Colitis, 11, pp.1293~1301 (2017)
- Allocca M, "Effectiveness of mesalazine, thiopurines and tumour necrosis factor antagonists in preventing post-operative Crohn’s disease recurrence in a real-life setting", Digestion, 96, pp.166~172 (2017)
- Regueiro M, "Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection", Gastroenterology, 150, pp.1568~1578 (2016)